Bibliography
- The Pharmaprojects database. Copyright © Informa UK Ltd
- Sheldon J, Barreiro P, Vincent V. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin Invest Drugs 2007;16:1171-81
- Fujiwara T, Sato A, el-Farrash M, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998;42:1340-5
- Sato A, Hammond J, Alexander TN, et al. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor. Antiviral Res 2006;70:66-74
- Priddy FH, Brown D, Kublin J, et al. Merck V520-016 Study Group. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008;46:1769-81
- Timm A, Enzinger C, Felder E, et al. Genetic stability of recombinant MVA-BN. Vaccine 2006;24:4618-21
- Yang W, Zhao Y, Fabrycki J, et al. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob Agents Chemother 2008;52:2043-52
- Fletcher S, Steffy K, Averett D. Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease. Curr Opin Investig Drugs 2006;7:702-8
- Fiorucci S, Antonelli E, Morelli O, et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA 2001;98:8897-902
- Koelle DM, Magaret A, McClurkan CL, et al. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects. Clin Vaccine Immunol 2008;15:773-82
- Goodman M. Pharma industry performance metrics: 2007-2012E. Nat Rev Drug Discov 2008;7:795
- Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008;455:613-9
- Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008;128:133-47
- Jensen DM, Ascione A. Future directions in therapy for chronic hepatitis C. Antivir Ther 2008;13(Suppl 1):31-6